Zobrazeno 1 - 10
of 41
pro vyhledávání: '"M. Deblock"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
V Massard, L Uwer, A Lesur, A Kieffer, M Deblock, Pauline Gilson, Alexandre Harlé, Julia Salleron, Maria Rios, JL Merlin
Publikováno v:
Cancer Research. 79:OT1-03
Activating ESR1 mutations have recently been reported as a key mechanism leading to Aromatase Inhibitor (AI) resistance. ESR1 mutations occur rarely in primary breast cancers. However, in large retrospective studies, ESR1 mutations occurred in up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eadf9b4ce911cb8c388021fa3418c416
https://doi.org/10.1158/1538-7445.sabcs18-ot1-03-02
https://doi.org/10.1158/1538-7445.sabcs18-ot1-03-02
Autor:
Pernelle Lavaud, Aude Flechon, G. Le Teuff, Karim Fizazi, Katty Malekzadeh, Gwenaelle Gravis, Giulia Baciarello, M. Deblock, S. Cyrille, Christine Chevreau, Ronan Flippot, Emeline Colomba
Publikováno v:
Annals of Oncology. 32:S680
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::514219800a4d35cf4693665c372efdf1
https://doi.org/10.1016/j.annonc.2021.08.051
https://doi.org/10.1016/j.annonc.2021.08.051
Autor:
M Atlassi, Philippe Follana, Rémy Largillier, B Salles, J Dauba, J-M Ferrero, A-C. Hardy-Bessard, Alain Lortholary, M Deblock, Olivier Capitain, R Herve
Publikováno v:
Cancer Research. 73:P3-13
Background: Weekly paclitaxel and capecitabine intermittent regimen is a safe and effective combination in first line treatment of MBC including triple negative cancer (Lortholary et al, Breast Cancer Res Treat 2012). In TNMBC, the combination of A w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa071c6b0196c2e490fd1cc51d148fb4
https://doi.org/10.1158/0008-5472.sabcs13-p3-13-07
https://doi.org/10.1158/0008-5472.sabcs13-p3-13-07
Autor:
T. Nguyen Tan Hon, Geraldine Martineau, Y. Tazi, G. Gravis, Marine Gross-Goupil, P. Beuzeboc, Aude Flechon, M. Deblock, Remy Delva, Christine Theodore, Tifenn Lharidon, F. Joly Lobbedez, Giulia Baciarello, Isabelle Borget, Caroline Cheneau, Philippe Barthélémy, Stéphane Culine, J.-F. Berdah, Karim Fizazi, E. Bompas
Publikováno v:
Web of Science
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee688bc627d0f336047c1d365d3af95
https://doi.org/10.1093/annonc/mdx370.019
https://doi.org/10.1093/annonc/mdx370.019
Autor:
M-A Mouret-Reynier, Thierry Petit, J-Y Pierga, Jérôme Lemonnier, Thomas Bachelot, T. Delozier, Patrick Soulié, Florence Lerebours, J. Bonneterre, E Charafe-Jauffret, J-M Ferrero, A-C. Hardy-Bessard, J.M. Boher, Bernard Asselain, P. Kerbrat, Gilles Romieu, J-C Eymard, A-L Martin, Florence Dalenc, M Deblock, Alain Lortholary, F Andre, Patrice Viens
Publikováno v:
Cancer Research. 71:P4-20
Background: Inflammatory breast cancer (IBC) is a relatively rare form of breast cancer. Because this disease exhibits angiogenic properties, bevacizumab (BEV) may improves the efficacy of neoadjuvant chemotherapy (CT) in IBC. Methods: Pts with HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b55a24ff6064bade2fe8843f063424a
https://doi.org/10.1158/0008-5472.sabcs11-p4-20-01
https://doi.org/10.1158/0008-5472.sabcs11-p4-20-01
Publikováno v:
Oncologie. 13:818-824
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::208c2e1774679ac621516d42bda843cc
https://doi.org/10.1007/s10269-011-2093-x
https://doi.org/10.1007/s10269-011-2093-x
Autor:
M. Deblock, M. S. Aapro
Publikováno v:
Annales françaises de médecine d'urgence. 1:229-231
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e87247ac836b659ff453c67ffa942f2
https://doi.org/10.1007/s13341-011-0086-4
https://doi.org/10.1007/s13341-011-0086-4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.